Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor

Enhanced Degradation of Platelet-Activating Factor in Serum from Diabetic Patients

“…This finding is similar to those obtained in two other studies, including patients suffer ing from peripheral atherosclerosis [18] and survivors of myocardial infarction [19]. These patients were characterized as diabet ics also by some changes in the serum lipo protein profile.…”

Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.

“…Although the capacity to degrade PAF was slightly elevated in atherosclerotic patients (47), the enzyme activity showed no significant change during asthmatic attacks, which caused a decrease in peak expiratory flow rate (Fig. 9).…”

Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2.

“…Separation ofHepG2-conditioned medium by gel filtration disclosed that PAF acetylhydrolase had an apparent molecular weight similar to plasma lipoproteins and that the activity was Plasma PAF acetylhydrolase activity has been shown to be higher in patients with dyslipoproteinemia (7) and atherosclerotic peripheral vascular disease (8), and lower in asthma (1 1). Also, this enzyme activity in plasma has been shown to correlate with the levels of LDL (9,39).…”

“…There are intra-and extracellular forms ofthis enzyme (6), and they may play an important role as a mechanism to regulate the levels of PAF. The activity of this enzyme in plasma has been reported to be higher in patients with dyslipoproteinemia (7), atherosclerotic diseases (8), ischemic stroke (9), and essential hypertension (10). It is reported to be lower in patients with severe bronchial asthma (1 1).…”